NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 100050, China.
Int J Mol Sci. 2024 May 9;25(10):5149. doi: 10.3390/ijms25105149.
Recombinant adeno-associated virus (rAAV) has emerged as a prominent vector for in vivo gene therapy, owing to its distinct advantages. Accurate determination of the rAAV genome titer is crucial for ensuring the safe and effective administration of clinical doses. The evolution of the rAAV genome titer assay from quantitative PCR (qPCR) to digital PCR (dPCR) has enhanced accuracy and precision, yet practical challenges persist. This study systematically investigated the impact of various operational factors on genome titration in a single-factor manner, aiming to address potential sources of variability in the quantitative determination process. Our findings revealed that a pretreatment procedure without genome extraction exhibits superior precision compared with titration with genome extraction. Additionally, notable variations in titration results across different brands of dPCR instruments were documented, with relative standard deviation (RSD) reaching 23.47% for AAV5 and 11.57% for AAV8. Notably, optimal operations about DNase I digestion were identified; we thought treatment time exceeding 30 min was necessary, and there was no need for thermal inactivation after digestion. And we highlighted that thermal capsid disruption before serial dilution substantially affected AAV genome titers, causing a greater than ten-fold decrease. Conversely, this study found that additive components of dilution buffer are not significant contributors to titration variations. Furthermore, we found that repeated freeze-thaw cycles significantly compromised AAV genome titers. In conclusion, a comprehensive dPCR titration protocol, incorporating insights from these impact factors, was proposed and successfully tested across multiple serotypes of AAV. The results demonstrate acceptable variations, with the RSD consistently below 5.00% for all tested AAV samples. This study provides valuable insights to reduce variability and improve the reproducibility of AAV genome titration using dPCR.
重组腺相关病毒 (rAAV) 因其独特的优势已成为体内基因治疗的主要载体。准确测定 rAAV 基因组滴度对于确保临床剂量的安全有效给药至关重要。rAAV 基因组滴度测定从定量 PCR(qPCR) 到数字 PCR(dPCR) 的发展提高了准确性和精密度,但仍存在实际挑战。本研究系统地以单因素方式研究了各种操作因素对基因组滴定的影响,旨在解决定量测定过程中潜在的变异性来源。我们的研究结果表明,与基因组提取滴定相比,不进行预处理的方法显示出更高的精密度。此外,还记录了不同品牌的 dPCR 仪器之间的滴定结果存在显著差异,AAV5 的相对标准偏差 (RSD) 达到 23.47%,AAV8 的 RSD 达到 11.57%。值得注意的是,确定了 DNase I 消化的最佳操作;我们认为处理时间超过 30 分钟是必要的,消化后无需进行热失活。并且我们强调在连续稀释之前进行热外壳破坏会极大地影响 AAV 基因组滴度,导致滴度降低十倍以上。相反,本研究发现稀释缓冲液的添加剂成分不是滴定变化的重要因素。此外,我们发现反复冻融循环会显著降低 AAV 基因组滴度。总之,提出了一种全面的 dPCR 滴定方案,该方案结合了这些影响因素的见解,并成功地在多种 AAV 血清型中进行了测试。结果表明,变化可接受,所有测试的 AAV 样本的 RSD 均保持在 5.00%以下。本研究为使用 dPCR 降低 AAV 基因组滴定的变异性和提高重现性提供了有价值的见解。